Uni-Bio Files for China Approval of Novel Osteoporosis Drug

Uni-Bio Science Group Limited has filed a New Drug Application with the CFDA for China approval of Uni-PTH, the company's proprietary treatment for osteoporosis. UniPTH is a 34 amino acid analogue of parathyroid hormone (PTH) that controls the level of calcium and phosphorus in the blood and vitamin D in the kidney. Founded in 2001, Uni-Bio is headquartered in Hong Kong with operations in China. The CFDA has accepted the application. More details.... Stock Symbol: (HK: 690) Share this with colleagues: // //